Table 5 Treatment-emergent adverse events with frequency of >5% in any treatment group.

Pairwise comparisons between treatments and placebo were not significant (P > 0.05). NOS, not otherwise specified.

Preferred
term, n (%)
Placebo
(n = 43)
LYA
(n = 39)
LYB
(n = 42)
Carprofen
(n = 39)
Emesis3 (7.0)6 (15.4)6 (14.3)3 (7.7)
Diarrhea5 (11.6)5 (12.8)5 (11.9)2 (5.1)
Polydipsia2 (4.7)3 (7.7)6 (14.3)2 (5.1)
Anorexia1 (2.3)3 (7.7)5 (11.9)1 (2.6)
Lethargy1 (2.3)3 (7.7)1 (2.4)1 (2.6)
Polyuria1 (2.3)0 (0)3 (7.1)1 (2.6)
Bacterial skin
infections
1 (2.3)0 (0)0 (0)2 (5.1)
Eye disorder
NOS
0 (0)0 (0)3 (7.1)0 (0)
Pruritus0 (0)2 (5.1)0 (0)0 (0)